BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20670091)

  • 1. Neutropenic enterocolitis during first-line chemotherapy with carboplatin and etoposide in small cell lung cancer.
    Baandrup L; Hauggaard A; Winberg BH; Holm B
    Acta Oncol; 2011 Apr; 50(3):465-7. PubMed ID: 20670091
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: 'A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small-cell lung cancer: a randomized trial'.
    Bregni M; Pedrazzoli P
    J Natl Cancer Inst; 2009 Jan; 101(1):67; author reply 67-8. PubMed ID: 19116385
    [No Abstract]   [Full Text] [Related]  

  • 4. An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?
    Groenendijk MR; Thunnissen E; Ylstra B; van de Wiel MA; Eijk PP; Paul MA; Smit EF; Postmus PE
    J Thorac Oncol; 2012 Aug; 7(8):e3-5. PubMed ID: 22797153
    [No Abstract]   [Full Text] [Related]  

  • 5. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
    Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
    Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].
    Tamiya A; Tsuya A; Nakamura Y; Kaira K; Naitou T; Murakami H; Takahashi T; Endo M; Yamamoto N
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1041-4. PubMed ID: 20567104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
    Chiappori AA; Schreeder MT; Moezi MM; Stephenson JJ; Blakely J; Salgia R; Chu QS; Ross HJ; Subramaniam DS; Schnyder J; Berger MS
    Br J Cancer; 2012 Feb; 106(5):839-45. PubMed ID: 22333598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer.
    Hainsworth JD; Hopkins LG; Thomas M; Greco FA
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 2):31-5. PubMed ID: 9516609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
    Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T;
    Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of small cell bronchogenic carcinoma in a patient on hemodialysis for chronic renal failure. Apropos of a case].
    Guillou B; Robinet G; Gouva S; Guillodo MP; Daniel C; Clavier J
    Rev Pneumol Clin; 1998 Sep; 54(4):215-8. PubMed ID: 9805752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
    Shao N; Jin S; Zhu W
    J Thorac Oncol; 2012 Feb; 7(2):470-2. PubMed ID: 22252565
    [No Abstract]   [Full Text] [Related]  

  • 14. Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.
    Takaoka E; Kawai K; Ando S; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2006 Jan; 36(1):60-3. PubMed ID: 16436462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
    Yoshida T; Yoh K; Goto K; Niho S; Umemura S; Ohmatsu H; Ohe Y
    Anticancer Res; 2013 Mar; 33(3):1175-9. PubMed ID: 23482799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study.
    Perey L; Rosti G; Lange A; Pampallona S; Bosquée L; Pasini F; Humblet Y; Hamdan O; Cetto GL; Marangolo M; Leyvraz S
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S40-3. PubMed ID: 8899170
    [No Abstract]   [Full Text] [Related]  

  • 19. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W
    Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
    J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.